SCHEMBL5534898

SCHEMBL5534898

[CH2]c1nc(-c2ccc(Cl)cc2)oc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 1/20 0.50
KDM4E B2RXH2 7/20 0.45
ALDH1A1 P00352 4/20 0.45
LMNA P02545 3/20 0.45
HPGD P15428 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
NR1H4 Q96RI1 1/20 0.45
HSD17B10 Q99714 3/20 0.44
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
NPSR1 Q6W5P4 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
MAOB P27338 1/20 0.43
XBP1 P17861 1/20 0.43
CYP3A4 P08684 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543992 0.81 NPC1 (0.48) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL5534902 0.81 KDM4E (0.59) TARBP2KDM4EALDH1A1LMNAHPGD
SCHEMBL3758086 0.81 KDM4E (0.51) TARBP2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5536092 0.80 NPC1 (0.50) ALDH1A1SMN1; SMN2NFKB1NFKB2RELA
SCHEMBL1863083 0.79 TP53 (0.47) KDM4EALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL5546864 0.78 KDM4E (0.53) TARBP2KDM4EALDH1A1LMNAHPGD
SCHEMBL5540713 0.77 HSD17B10 (0.53) TARBP2KDM4EALDH1A1LMNAHPGD
SCHEMBL1868373 0.77 PTPN1 (0.51) KDM4EALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL1807664 0.76 NPC1 (0.36) TARBP2KDM4EALDH1A1SMN1; SMN2HSD17B10
SCHEMBL13179907 0.75 HSD17B10 (0.58) TARBP2KDM4EALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TARBP2 2095/4885KDM4E 4854/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.